Andrew Davis

Andrew Davis is an experienced business leader currently serving as the Chief Business Officer at Dynavax Technologies since November 2024, overseeing Business Development and Strategy as a member of the executive team. Additionally, Andrew holds a board member position at UTILITY therapeutics, which focuses on combating multi-drug resistant bacterial infections. Previously, Andrew was the Senior Vice President and Chief Business Officer at Ironwood Pharmaceuticals from May 2021 to November 2024, where responsibilities included leadership of commercial, business development, mergers and acquisitions, and strategic portfolio management. Andrew's extensive background includes roles at Biomarck Pharmaceuticals, iNova Pharmaceuticals, Merck, and Bausch Health Companies, where significant achievements include leading over 60 transactions valued at more than $30 billion. Andrew's career began at McKinsey & Company, contributing to pharmaceutical and medical products analyses, and Andrew holds a Bachelor of Arts in Economics from Boston University.